Abstract
This prospective cohort study evaluated rifampin pharmacokinetics in pregnant and nonpregnant women with tuberculosis in India. Pregnant women had significantly lower drug exposure, with <20% of the participants achieving target concentrations at any trimester. Findings highlight potential underdosing in pregnancy and underscore the need for dedicated pharmacokinetics studies in pregnancy, and revised rifampin dosing guidelines.